Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for Hypereosinophilic Syndrome: Multicentre Randomized Double-blind Phase 3 Trial
2019-002039-27Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benralizumab in hypereosinophilic syndrome (HES) (2 arms), sponsored by AstraZeneca. Primary endpoint: Time to first HES worsening/flare. Started Nov 2019; status: active.
02
Drugs
benralizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on 2019-002039-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002039-27.